Headlines about VBI Vaccines (NASDAQ:VBIV) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. VBI Vaccines earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.6744127027066 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
A number of research analysts recently commented on the company. Zacks Investment Research cut VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. BidaskClub cut VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. BMO Capital Markets assumed coverage on VBI Vaccines in a research note on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 target price on the stock. Finally, Canaccord Genuity assumed coverage on VBI Vaccines in a research note on Wednesday, November 1st. They set a “buy” rating and a $10.00 price objective on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. VBI Vaccines currently has a consensus rating of “Hold” and a consensus target price of $8.75.
VBI Vaccines (NASDAQ:VBIV) opened at $4.46 on Friday. VBI Vaccines has a 12 month low of $3.04 and a 12 month high of $6.60. The stock has a market capitalization of $280.10, a PE ratio of -6.11 and a beta of 1.75. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.97 and a current ratio of 1.03.
In other news, CEO Jeff Baxter bought 10,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was bought at an average cost of $3.89 per share, for a total transaction of $38,900.00. Following the completion of the acquisition, the chief executive officer now owns 140,646 shares in the company, valued at approximately $547,112.94. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Life Sciences Maste Perceptive bought 3,100,000 shares of the company’s stock in a transaction dated Thursday, October 26th. The shares were purchased at an average price of $3.05 per share, with a total value of $9,455,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 4,080,738 shares of company stock valued at $12,480,151. 34.10% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “VBI Vaccines (VBIV) Receives Daily Media Sentiment Score of 0.14” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://ledgergazette.com/2018/01/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-vbi-vaccines-vbiv-share-price.html.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.